Inosine pranobex

Identification

Summary

Inosine pranobex is a medication used to treat subacute sclerosing panencephalitis.

Brand Names
Imunovir
Generic Name
Inosine pranobex
DrugBank Accession Number
DB13156
Background

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1115.249
Monoisotopic: 1114.554641092
Chemical Formula
C52H78N10O17
Synonyms
  • IAD
  • Inosine acedobene dimepranol
  • Inosine pranobex
  • Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
  • Inosiplex
  • Isoprinosine
  • Methisoprinol
External IDs
  • NP-113
  • NPT-10381

Pharmacology

Indication

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Mechanism of action

Inosine pranobex stimulates cell-mediated immune processes to viral infections.

Absorption

Rapidly absorbed from GIT

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Via urine

Half-life

50 min

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Mouse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ImunovirTablet500 mgOralKora Healthcare2000-01-25Not applicableCanada flag
IsoprinosineTablet500 mgOralNewport Pharmaceuticals International1997-06-052000-02-04Canada flag
Isoprinosine Tab 500mgTablet500 mg / tabOralSystemed Inc.1993-12-311996-09-10Canada flag
Isoprinosine Tab 500mgTablet500 mgOralNewport Pharms International Inc.1983-12-311996-09-10Canada flag

Categories

ATC Codes
J05AX05 — Inosine pranobex
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans
show 14 more
Substituents
1,2-aminoalcohol / 6-oxopurine / Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzoic acid / Benzoic acid or derivatives
show 38 more
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
W1SO0V223F
CAS number
36703-88-5
InChI Key
YLDCUKJMEKGGFI-KSIULYHRSA-N
InChI
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
IUPAC Name
tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
SMILES
C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O

References

General References
  1. ChemIDplus [Link]
  2. Pubchem [Link]
KEGG Drug
D01995
PubChem Compound
131704326
PubChem Substance
347829266
ChemSpider
58829622
RxNav
6048
Wikipedia
Inosine_pranobex

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Not Yet RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
3Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Recurrent Upper and Lower Respiratory Tract Infections (RTIs)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral250 mg/5ml
TabletOral500 mg / tab
SyrupOral
SyrupOral5 g
TabletOral
Capsule
CreamTopical10 %
CreamTopical20 %
GranuleOral1 g
Granule, for solutionOral1 g/5g
InjectionIntramuscular; Intravenous1 g/5ml
InjectionIntramuscular; Intravenous500 mg/5ml
InsertVaginal1500 mg
SyrupOral5 %
TabletOral750 MG
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-2.5ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.93ChemAxon
pKa (Strongest Basic)0.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area129.2 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity61.33 m3·mol-1ChemAxon
Polarizability24.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on December 04, 2016 00:28 / Updated on October 16, 2021 12:31